Last update 29 Aug 2025

Nanjing Angke Immune Biopharmaceutical Co., Ltd.

Subsidiary Company|2022|Jiangsu Sheng, China|
www.acroimmune.cn

Overview

Tags

Neoplasms
Bispecific antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms1
Top 5 Drug TypeCount
Bispecific antibody1
Top 5 TargetCount
PD-1 x VEGF1

Related

1
Drugs associated with Nanjing Angke Immune Biopharmaceutical Co., Ltd.
AI-081
Target
PD-1 x VEGF
Mechanism
PD-1 modulators [+1]
Active Org.
Nanjing Angke Immune Biopharmaceutical Co., Ltd. [+1]
Originator Org.
OncoC4, Inc.OncoC4, Inc.
Active Indication
Advanced Malignant Solid Neoplasm
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Nanjing Angke Immune Biopharmaceutical Co., Ltd.
CTR20253261
/ Not yet recruitingPhase 1
抗PD-1/VEGF双特异性抗体AI-081在晚期实体瘤参与者中的安全性、药代动力学及疗效的I/II期临床研究
[Translation] A Phase I/II clinical study of the safety, pharmacokinetics, and efficacy of the anti-PD-1/VEGF bispecific antibody AI-081 in participants with advanced solid tumors
100 Clinical Results associated with Nanjing Angke Immune Biopharmaceutical Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Nanjing Angke Immune Biopharmaceutical Co., Ltd.
Login to view more data
100 Deals associated with Nanjing Angke Immune Biopharmaceutical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Nanjing Angke Immune Biopharmaceutical Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
AI-081
 ( PD-1 x VEGF )		Advanced Malignant Solid Neoplasm
More
Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free